Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Booster Vaccination with 1790GAHB in Healthy Adults
NCT03089879Phase 1Completed
- Sponsor
- GSK
- Start
- Mar 2017
- Primary completion
- Aug 2017
- Modality
- Lipid-based Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of GVGH Shigella sonnei 1790GAHB vaccine in shigellosis (3 arms), sponsored by GSK. Primary endpoint: Concentrations of Immunoglobulin (IgG) Against Lipopolysaccharide (LPS) S. Sonnei O-antigen at Day 8. Started Mar 2017; status: completed.
02
Drugs
GVGH Shigella sonnei 1790GAHB vaccine
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT03089879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03089879.